Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2017 Nov 22;17(2):443–454. doi: 10.1158/1535-7163.MCT-17-0560

Figure 4. CA3 preferentially inhibits CSC properties enriched in radiation-resistant EAC cells.

Figure 4

A. The cells proliferation and viability (OD490) were measured in Flo-1 and Flo-1 XTR, the radiation resistant cells at 3 day and 6 day using MTS assay respectively as described in Materials&Methods. B. Representative images (top) and quantification (low) of tumor sphere formation in Flo-1 and Flo-1 XTR cells were demonstrated. C. YAP transcriptional activity was determined by co-transfection of Gal4-Tead and 5×UAS-luciferase and YAP1 cDNA in Flo-1-P and Flo-1 XTR cells treated with CA3 at dosage indicated, D. Cell growth inhibition in both Flo-1-P and Flo-1 XTR cells treated with CA3 at dosage indicated was determined using MTS assay as described in Materials&Methods; E. Immunoblotting for YAP1 and phospho-EGFR and phosph-S6 in Flo-1-P and Flo-1 XTR cells treated with CA3 at dosage indicated. F. Representative images (top) and quantification (low) of tumor sphere formation in Flo-1 and Flo-1 XTR cells treated with CA3 at dosage indicated. Experiments were repeated three times. G. Flo-1, Flo-1 XTR and Flo-1 XTR cells treated with CA3 at 0.5µM for 48 hours and then labeling with ALDH1 using ALDH1 labeling kit.